Nmr Metabolomics of Renal Cancer: an Overview

References

• Ljungberg B , CowanNC, HanburyDCet al. EAU Guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58 (3), 398–406 (2010).
   PubMed Web of Science ®Google Scholar
• Ather MH , MasoodN, SiddiquiT. Current management of advanced and metastatic renal cell carcinoma. Urol. J. 7 (1), 1–9 (2010).
   PubMed Web of Science ®Google Scholar
• Moch H . An overview of renal cell cancer: pathology and genetics. Semin. Cancer Biol. 23 (1), 3–9 (2013).
   PubMed Web of Science ®Google Scholar
• Algaba F , AkazaH, López-BeltránAet al. Current pathology keys of renal cell carcinoma. Eur. Urol. 60 (4), 634–643 (2011).
   PubMed Web of Science ®Google Scholar
• Basso M , CassanoA, BaroneC. A survey of therapy for advanced renal cell carcinoma. Urol. Oncol. 28 (2), 121–133 (2010).
   PubMed Web of Science ®Google Scholar
• Adam A , DixonAK, GillardJH, Schaefer-ProkopCM. Grainger & Allison’s Diagnostic Radiology. Elsevier, PA, USA (2014).
   Google Scholar
• Cairns P . Renal cell carcinoma. Cancer Biomark. 9 (1–6), 461–473 (2010).
   PubMed Web of Science ®Google Scholar
• Vasudev NS , BanksRE. Biomarkers of renal cancer. In : Biomarkers in Kidney Disease. EdelsteinCL ( Ed.). Academic Press, CA, USA, 313–350 (2011).
   Google Scholar
• Cohen HT , McgovernFJ. Renal-cell carcinoma. N. Engl. J. Med. 353 (23), 2477–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Di Napoli A , SignorettiS. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer115 (10 Suppl.), 2290–2297 (2009).
   PubMed Web of Science ®Google Scholar
• Weiss RH , KimK. Metabolomics in the study of kidney diseases. Nat. Rev. Nephrol. 8 (1), 22–33 (2012).
   Web of Science ®Google Scholar
• Monteiro M , CarvalhoM, de Lourdes BastosM, Guedes de PinhoP. Biomarkers in renal cell carcinoma: a metabolomics approach. Metabolomics10 (6), 1210–1222 (2014).
   Web of Science ®Google Scholar
• Nicholson JK , LindonJC, HolmesE. ‘Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica29 (11), 1181–1189 (1999).
   PubMed Web of Science ®Google Scholar
• Dunn WB , BroadhurstDI, AthertonHJ, GoodacreR, GriffinJL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 40 (1), 387–426 (2011).
   PubMed Web of Science ®Google Scholar
• Larive CK , BardingGA, DingesMM. NMR spectroscopy for metabolomics and metabolic profiling. Anal. Chem. 87 (1), 133–146 (2015).
   PubMed Web of Science ®Google Scholar
• Raterink R-J , LindenburgPW, VreekenRJ, RamautarR, HankemeierT. Recent developments in sample-pretreatment techniques for mass spectrometry-based metabolomics. Trends Analyt. Chem. 61, 157–167 (2014).
   Web of Science ®Google Scholar
• Johnson CH , IvanisevicJ, BentonHP, SiuzdakG. Bioinformatics: the next frontier of metabolomics. Anal. Chem. 87 (1), 147–156 (2015).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144 (5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Cantor JR , SabatiniDM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2 (10), 881–898 (2012).
   PubMed Web of Science ®Google Scholar
• Ng D , PasikantiK, ChanE. Trend analysis of metabonomics and systematic review of metabonomics-derived cancer marker metabolites. Metabolomics7 (2), 155–178 (2011).
   Web of Science ®Google Scholar
• Moestue S , SitterB, BathenTF, TessemMB, GribbestadIS. HR MAS MR spectroscopy in metabolic characterization of cancer. Curr. Top. Med. Chem. 11 (1), 2–26 (2011).
   PubMed Web of Science ®Google Scholar
• Blekherman G , LaubenbacherR, CortesDet al. Bioinformatics tools for cancer metabolomics. Metabolomics7 (3), 329–343 (2011).
   PubMed Web of Science ®Google Scholar
• O’connell TM . Recent advances in metabolomics in oncology. Bioanalysis4 (4), 431–451 (2012).
   PubMed Web of Science ®Google Scholar
• Duarte IF , GilAM. Metabolic signatures of cancer unveiled by NMR spectroscopy of human biofluids. Prog. Nucl. Magn. Reson. Spectrosc. 62, 51–74 (2012).
   PubMed Web of Science ®Google Scholar
• Liesenfeld DB , HabermannN, OwenRW, ScalbertA, UlrichCM. Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol. Biomarkers Prev. 22 (12), 2182–2201 (2013).
   PubMed Web of Science ®Google Scholar
• Armitage EG , BarbasC. Metabolomics in cancer biomarker discovery: current trends and future perspectives. J. Pharm. Biomed. Anal. 87, 1–11 (2014).
   PubMed Web of Science ®Google Scholar
• Patel S , AhmedS. Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. J. Pharm. Biomed. Anal. 107, 63–74 (2015).
   PubMed Web of Science ®Google Scholar
• Chan ECY , PasikantiKK, HongYet al. Metabonomic profiling of bladder cancer. J. Proteome Res. 14 (2), 587–602 (2015).
   PubMed Web of Science ®Google Scholar
• Denkert C , BucherE, HilvoMet al. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 4 (4), 37 (2012).
   PubMedGoogle Scholar
• Williams M , ReevesR, ResarL, HillHHJr Metabolomics of colorectal cancer: past and current analytical platforms. Anal. Bioanal. Chem. 405 (15), 5013–5030 (2013).
   PubMed Web of Science ®Google Scholar
• Ni Y , XieG, JiaW. Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J. Proteome Res. 13 (9), 3857–3870 (2014).
   PubMed Web of Science ®Google Scholar
• Wang X , ZhangA, SunH. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology57 (5), 2072–2077 (2013).
   PubMed Web of Science ®Google Scholar
• Kimhofer T , FyeH, Taylor-RobinsonS, HolmesE. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br. J. Cancer112 (7), 1141–1156 (2015).
   PubMed Web of Science ®Google Scholar
• Duarte IF , RochaCM, GilAM. Metabolic profiling of biofluids: potential in lung cancer screening and diagnosis. Expert Rev. Mol. Diagn. 13 (7), 737–748 (2013).
   PubMed Web of Science ®Google Scholar
• Di Gangi IM , VrhovsekU, PazienzaV, MattiviF. Analytical metabolomics-based approaches to pancreatic cancer. Trends Analyt. Chem. 55 (0), 94–116 (2014).
   Google Scholar
• Defeo EM , WuCL, McDougalWS, ChengLL. A decade in prostate cancer: from NMR to metabolomics. Nat. Rev. Urol. 8 (6), 301–311 (2011).
   PubMed Web of Science ®Google Scholar
• Spur EM , DecelleEA, ChengLL. Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry. Eur. J. Nucl. Med. Mol. Imaging40 (Suppl. 1), S60–S71 (2013).
   PubMedGoogle Scholar
• Kumar V , DwivediDK, JagannathanNR. High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer. NMR Biomed. 27 (1), 80–89 (2014).
   PubMed Web of Science ®Google Scholar
• Decelle EA , ChengLL. High-resolution magic angle spinning 1H MRS in prostate cancer. NMR Biomed. 27 (1), 90–99 (2014).
   PubMed Web of Science ®Google Scholar
• Wojakowska A , ChekanM, WidlakP, PietrowskaM. Application of metabolomics in thyroid cancer research. Int. J. Endocrinol. 2015, 13 (2015).
   Web of Science ®Google Scholar
• Rocha CM , BarrosAS, GoodfellowBJet al. NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. Carcinogenesis36 (1), 68–75 (2015).
   PubMed Web of Science ®Google Scholar
• Cuperlovic-Culf M , FergusonD, CulfA, MorinPJr, TouaibiaM. 1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics. J. Biol. Chem. 287 (24), 20164–20175 (2012).
   PubMed Web of Science ®Google Scholar
• Elkhaled A , JalbertL, ConstantinAet al. Characterization of metabolites in infiltrating gliomas using ex vivo (1)H high-resolution magic angle spinning spectroscopy. NMR Biomed. 27 (5), 578–593 (2014).
   PubMed Web of Science ®Google Scholar
• Ganti S , WeissRH. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol. Oncol. 29 (5), 551–557 (2011).
   PubMed Web of Science ®Google Scholar
• Sudarshan S , KaramJA, BrugarolasJet al. Metabolism of kidney cancer: from the lab to clinical practice. Eur. Urol. 63 (2), 244–251 (2013).
   PubMed Web of Science ®Google Scholar
• Lutz NW , FranksSE, FrankMH, PomerS, HullWE. Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays. Magma18 (3), 144–161 (2005).
   PubMedGoogle Scholar
• Moka D , VorreutherR, SchichaHet al. Biochemical classification of kidney carcinoma biopsy samples using magic-angle-spinning 1H nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 17 (1), 125–132 (1998).
   PubMed Web of Science ®Google Scholar
• Kobayashi T , HonkeK, KamioKet al. Sulfolipids and glycolipid sulfotransferase activities in human renal cell carcinoma cells. Br. J. Cancer67 (1), 76–80 (1993).
   PubMed Web of Science ®Google Scholar
• Tate AR , FoxallPJ, HolmesEet al. Distinction between normal and renal cell carcinoma kidney cortical biopsy samples using pattern recognition of (1)H magic angle spinning (MAS) NMR spectra. NMR Biomed. 13 (2), 64–71 (2000).
   PubMed Web of Science ®Google Scholar
• Righi V , MucciA, SchenettiLet al. Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues. Anticancer Res. 27 (5A), 3195–3204 (2007).
   PubMed Web of Science ®Google Scholar
• Righi V , MucciA, SchenettiLet al. Identification of mobile lipids in human cancer tissues by ex vivo diffusion edited HR-MAS MRS. Oncol. Rep. 22 (6), 1493–1496 (2009).
   PubMed Web of Science ®Google Scholar
• Ammann LP , MerrittM. StePSIM – a method for stepwise peak selection and identification of metabolites in 1H NMR spectra. Metabolomics3 (1), 1–11 (2007).
   Web of Science ®Google Scholar
• Gao H , DongB, JiaJet al. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. J. Cancer Res. Clin. Oncol. 138 (5), 753–761 (2012).
   PubMed Web of Science ®Google Scholar
• Sullentrop F , MokaD, NeubauerSet al. 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed. 15 (1), 60–68 (2002).
   PubMed Web of Science ®Google Scholar
• Gao H , DongB, LiuX, XuanH, HuangY, LinD. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal. Chim. Acta624 (2), 269–277 (2008).
   PubMed Web of Science ®Google Scholar
• Zira AN , TheocharisSE, MitropoulosD, MigdalisV, MikrosE. 1H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J. Proteome Res. 9 (8), 4038–4044 (2010).
   PubMed Web of Science ®Google Scholar
• Süllentrop F , HahnJ, MokaD. In vitro and in vivo (1)H-MR spectroscopic examination of the renal cell carcinoma. Int. J. Biomed. Sci. 8 (2), 94–108 (2012).
   PubMedGoogle Scholar
• Atzori L , MussapM, NotoAet al. Clinical metabolomics and urinary NGAL for the early prediction of chronic kidney disease in healthy adults born ELBW. J. Matern. Fetal Neonatal Med. 24 (Suppl. 2), 40–43 (2011).
   PubMedGoogle Scholar
• Mutsaers HA , EngelkeUF, WilmerMJet al. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3–4 chronic kidney disease patients. PLoS ONE8 (8), e71199 (2013).
   PubMed Web of Science ®Google Scholar
• Kim JA , ChoiHJ, KwonYK, RyuDH, KwonT-H, HwangG-S. 1H NMR-based metabolite profiling of plasma in a rat model of chronic kidney disease. PLoS ONE9 (1), e85445 (2014).
   PubMed Web of Science ®Google Scholar
• Liu X , ZhongF, TangXLet al. Cordyceps sinensis protects against liver and heart injuries in a rat model of chronic kidney disease: a metabolomic analysis. Acta Pharmacol. Sin. 35 (5), 697–706 (2014).
   PubMed Web of Science ®Google Scholar
• Posada-Ayala M , ZubiriI, Martin-LorenzoMet al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int. 85 (1), 103–111 (2014).
   PubMed Web of Science ®Google Scholar
• Sui W , LiL, CheWet al. A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy. Clinics67 (4), 363–373 (2012).
   PubMed Web of Science ®Google Scholar
• Li L , SuiW, CheWet al. 1H NMR-based metabolic profiling of human serum before and after renal transplantation. Asaio J. 59 (3), 286–293 (2013).
   PubMed Web of Science ®Google Scholar
• Makinen VP , TynkkynenT, SoininenPet al. Sphingomyelin is associated with kidney disease in Type 1 diabetes (The FinnDiane study). Metabolomics8 (3), 369–375 (2012).
   PubMed Web of Science ®Google Scholar
• Makinen VP , TynkkynenT, SoininenPet al. Metabolic diversity of progressive kidney disease in 325 patients with Type 1 diabetes (the FinnDiane Study). J. Proteome Res. 11 (3), 1782–1790 (2012).
   PubMed Web of Science ®Google Scholar
• Makinen VP , SoininenP, KangasAJet al. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in Type 1 diabetes: the FinnDiane Study. J. Intern. Med. 273 (4), 383–395 (2013).
   PubMed Web of Science ®Google Scholar
• Xu J , ZhangJ, CaiS, DongJ, YangJY, ChenZ. Metabonomics studies of intact hepatic and renal cortical tissues from diabetic db/db mice using high-resolution magic-angle spinning 1H NMR spectroscopy. Anal. Bioanal. Chem. 393 (6–7), 1657–1668 (2009).
   PubMed Web of Science ®Google Scholar
• Sonkar K , BehariA, KapoorVK, SinhaN. 1H NMR metabolic profiling of human serum associated with benign and malignant gallstone diseases. Metabolomics9 (2), 515–528 (2013).
   Web of Science ®Google Scholar